More info
Active ingredients
Dihydroergocriptine + Caffeine
Release form
Pills
Composition
Active ingredient: Alpha-dihydroergocriptine (Alpha-dihydroergocryptine), Caffeine (Caffeine). Concentration of active ingredient (mg): Alpha-dihydroergocriptine - 4 mg, Caffeine - 40 mg
Pharmacological effect
Combined drug. Dihydroergocriptine a-mesylate, a dihydrogen ergot derivative, blocks a1 and a2 adrenoreceptors. It has dopaminergic, serotonergic action, reduces platelet aggregation and red blood cells, reduces vascular permeability, increases the number of functioning capillaries, improves blood circulation and metabolic processes in the brain, increases the resistance of brain tissue to hypoxia. Caffeine has a psychostimulant and analeptic effect, enhances the excitation processes in the cerebral cortex - increases mental and physical performance, reduces fatigue and drowsiness, increases the reflex excitability of the spinal cord, stimulates the respiratory and vasomotor centers, and has a diuretic effect.
Pharmacokinetics
When taken orally, the absorption of dihydroergocriptine is accelerated in the presence of caffeine (time to reach a maximum concentration of 0.5 hours). The maximum concentration after ingestion of 8 mg of dihydroergocriptine is 227 pg / ml, and the half-life from plasma is less than 2 hours.
Indications
Cerebrovascular insufficiency (including due to cerebral atherosclerosis), consequences of cerebral circulation disorders, vestibular and labyrinth disorders (dizziness, tinnitus, hypoacusia) of ischemic origin, Meniere's disease.
Contraindications
Increased individual sensitivity to the components of the drug, signs of valvular heart disease detected by echocardiography performed prior to the use of the drug.
Precautionary measures
It was reported that rarely with long-term treatment with high-dose dihydroergocriptine, pleural and pericardial effusion, as well as pleural and pulmonary fibrosis and constrictive pericarditis, were observed with high doses. Patients with unexplained pleural-pulmonary disorders should be examined, and the need to discontinue treatment with dihydroergocriptine should be discussed.Rare cases of retroperitoneal fibrosis have been reported with high doses of the drug for a long time. To make a diagnosis of retroperitoneal fibrosis, it is necessary to monitor this category of patients for the presence of clinical signs of retroperitoneal fibrosis (for example, back pain, lower extremity edema, renal failure). If any fibrotic retroperitoneal changes are suspected, treatment with dihydroergocriptine should be discontinued. Athletes should be warned that the drug contains a substance that can induce a positive reaction in drug screening tests. Avoid taking the drug on an empty stomach.
Dosage and administration
Inside (with meals, with a small amount of liquid), 12-1 tablet 2 times a day. Duration of treatment is 2-3 months, if necessary, treatment can be carried out 1-2 times a year.
Side effects
Nausea, gastralgia, dyspepsia, dizziness, agitation, headache, allergic reactions, tachycardia, hypotension.
Overdose
Symptoms: may cause vomiting. Treatment: symptomatic.
Interaction with other drugs
With the simultaneous appointment of vazobral and antihypertensive drugs may develop arterial hypotension. Caffeine weakens the effect of hypnotic drugs.
special instructions
Vasobral has a vasodilating effect, without affecting the systemic arterial pressure. Appointment of Vasobyl patients with hypertension does not exclude the need for the use of antihypertensive drugs. Caffeine contained in the drug can cause sleep disturbance, tachycardia.